(Total Views: 465)
Posted On: 05/30/2025 11:21:53 AM
Post# of 153887
Quote:
The DSMB can then recommend restricting further enrollment to a single dose level, should they identify a signal of superior activity in either one of the treatment arms.
Let's say the DSMB recommends that everyone gets put on 700 mg, which I trust will happen. That info would of course be available to the CRO, who would have to carry it out. Would CYDY know that 700 mg has signalled "superior activity"? Would it be bad faith or even degrade the trial if the company announced that fact about a month + into the trial?
(3)
(0)
